HOWL (Werewolf Therapeutics) EPS (Basic) : $-1.63 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics EPS (Basic)?

Werewolf Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-0.46. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.63.

Werewolf Therapeutics's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.46. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.66.

Werewolf Therapeutics's EPS without NRI for the three months ended in Dec. 2024 was $-0.46. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -1.65.

During the past 3 years, the average EPS without NRI Growth Rate was 47.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Werewolf Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 47.10% per year. The lowest was 2.20% per year. And the median was 14.50% per year.

Werewolf Therapeutics EPS (Basic) Historical Data

The historical data trend for Werewolf Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics EPS (Basic) Chart

Werewolf Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-3.15

-10.94

-1.86

-1.05

-1.63

Werewolf Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.33	-0.39	-0.40	-0.38	-0.46

Werewolf Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Werewolf Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-70.515	-	0)	/	43.332
	=	-1.63

Werewolf Therapeutics's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-20.4	-	0)	/	44.487
	=	-0.46

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.63

Werewolf Therapeutics (NAS:HOWL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Werewolf Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Werewolf Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472

Website

https://www.werewolftx.com

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake	officer: Chief Technology Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard	officer: Chief Operating Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc	10 percent owner	800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco	director	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin	10 percent owner	6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus	director, 10 percent owner	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin	director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520